Expert CMC advice on quality dossier preparation in support of a Compassionate Use Program in France.

Case studies - 28 May 2019

Expert CMC advice on quality dossier preparation in support of a Compassionate Use Program in France.

In the context of PRIME, a European biotechnological company entrusted BlueReg CMC team with the task of bringing the available quality data package of a synthetic peptide to global registration prerequisites for the next steps of development (the Compassionate use program in France, Phase III global program, registration in Europe and US) and to write the Quality part of the IMPD for early access submission in France.

 

Did you like this article? Share on social networks:


BlueReg undertakes to comply with the regulations in force applicable to the processing of personal data and, in particular, Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 applicable as from 25 May 2018 (hereinafter, "the General Data Protection Regulations" or GPDR) and the national laws resulting therefrom.
Any inquiries, correction or declaration of event related to personal data processed should be sent to: br-dataprivacy@blue-reg.com
Learn more

Discover our last white Paper

Learn more